Fig. 3From: Therapeutic efficacy of dose-reduced adjuvant chemotherapy with S-1 in patients with pancreatic cancer: a retrospective studyOverall survival (OS) of patients according to the total dose ratio (TDI) of adjuvant chemotherapy (AC). The high-TDI group shows significantly better OS than the low-TDI group and AC(-) group (median, 53 months vs. 20 months, P < 0.001) and AC (-) group (median, 25 months, vs. high-TDI, P < 0.001)Back to article page